1. Home
  2. ANIK vs NYXH Comparison

ANIK vs NYXH Comparison

Compare ANIK & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

HOLD

Current Price

$20.86

Market Cap

200.9M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.54

Market Cap

165.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIK
NYXH
Founded
1983
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.9M
165.0M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
ANIK
NYXH
Price
$20.86
$1.54
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$17.00
$9.33
AVG Volume (30 Days)
95.8K
247.6K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
80.16
N/A
EPS
N/A
N/A
Revenue
$112,819,000.00
N/A
Revenue This Year
$5.98
$213.98
Revenue Next Year
$7.42
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.56
$1.26
52 Week High
$22.88
$6.87

Technical Indicators

Market Signals
Indicator
ANIK
NYXH
Relative Strength Index (RSI) 53.85 44.06
Support Level $20.13 $1.49
Resistance Level $22.70 $1.70
Average True Range (ATR) 0.86 0.08
MACD -0.25 -0.01
Stochastic Oscillator 28.81 8.33

Price Performance

Historical Comparison
ANIK
NYXH

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: